Therapy-related CD7+ acute myeloid leukemia with trisomy 8 following acute monocytic leukemia.
We report a patient who developed CD7+ therapy-related acute myeloid leukemia (t-AML) with trisomy 8 after chemotherapy for AML.
Tanaka
M
M
First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama 236-0004, Japan.
Kanamori
H
H
Yamaji
S
S
Fujimaki
K
K
Tomita
N
N
Fujisawa
S
S
Ishigatsubo
Y
Y
D019011:Antigens, CD7 / Q000032:analysis; D014408:Biomarkers, Tumor / Q000032:analysis; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics; D003561:Cytarabine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D006801:Humans; D007948:Leukemia, Monocytic, Acute / Q000175:diagnosis / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000139:chemically induced* / Q000175:diagnosis / Q000235:genetics*; D015122:Mercaptopurine / Q000627:therapeutic use; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis / Q000235:genetics*; D011239:Prednisolone / Q000627:therapeutic use; D014314:Trisomy / Q000235:genetics
D019011:Antigens, CD7; D014408:Biomarkers, Tumor; D003561:Cytarabine; D011239:Prednisolone; C015019:enocitabine; D015122:Mercaptopurine; D003630:Daunorubicin